A B S T R A C T Plasma from individuals with high molecular weight (HMW) kininogen deficiency has been reported to be deficient in prekallikrein as measured by radial immunodiffusion, prekallikrein coagulant activity, and/or kaolin-activated arginine esterase activity. Addition of HMW kininogen increased the apparent prekallikrein activity in native normal plasma (as measured by esterase activity) but not in normal plasma in which inhibitors were inactivated. The apparent prekallikrein antigen concentration (as measured by radial immunodiffusion or electroimmunodiffusion) increased upon addition of HMW kininogen. Immunoelectrophoresis as well as gel filtration of normal plasma revealed the presence of free prekallikrein (17-38% of the total) in addition to the HMW kininogen-prekallikrein complex previously reported.
Addition of HMW kininogen increased the apparent prekallikrein activity in native normal plasma (as measured by esterase activity) but not in normal plasma in which inhibitors were inactivated. The apparent prekallikrein antigen concentration (as measured by radial immunodiffusion or electroimmunodiffusion) increased upon addition of HMW kininogen. Immunoelectrophoresis as well as gel filtration of normal plasma revealed the presence of free prekallikrein (17-38% of the total) in addition to the HMW kininogen-prekallikrein complex previously reported.
This study emphasizes the influence of HMW kininogen on both functional and immunologic determinations of prekallikrein.
INTRODUCTION
Plasma from individuals with severe deficiency of high molecular weight kininogen (HMW kininogen)l have abnormalities in all Factor XII-dependent pathways including coagulation, kinin formation, fibrinolysis, and permeability enhancement (1) (2) (3) (4) (5) . Associated prekallikrein deficiency, although insufficient to account for these abnormalities, has been described in all but one of these individuals (3) . Close functional relationships, however, do exist between these two proteins. The activated form of prekallikrein, kallikrein, is the enzyme which releases bradykinin from HMW kininogen (6) , whereas HMW kininogen in turn potentiates the activation of prekallikrein on a surface by Factor XII (7, 8) or in the fluid phase by Factor XII fragments (XIIf) (9) . The former activity may involve the increased binding ofprekallikrein to the surface when complexed with HMW kininogen. The intimate physical and functional interrelations between these two proteins suggested that the assay methods used for prekallikrein IAbbreviations used in this paper: B-2, sodium barbital buffer, pH 8.6; Cl-inhibitor, CIS-inactivator; EID, electroimmunodiffusion; HMW kininogen, high molecular weight kininogen; XIIf, Factor XII fragments; IEP, immunoelectrophoresis; RID, radial immunodiffusion; TAMe, p-tosyl-Larginine methyl ester. may be affected by the presence or absence of HMW kininogen and give rise to an apparent deficiency of prekallikrein in HMW kininogen-deficient plasma.
This study provides evidence that both immunochemical and functional assays are thus influenced and that the addition of purified HMW kininogen to plasma congenitally deficient in that protein corrects not only the defects in the Factor XII-dependent pathways, but also results in normalization of the apparent prekallikrein deficiency. Furthermore, the nature of prekallikrein in normal plasma has also been reinvestigated, both functionally and immunochemically. Plasma Plasma. Normal human plasma was obtained from healthy donors, with their written informed consent, as previously described (9) and frozen in 1-ml portions. In the experiments where fresh plasma was used, it was collected in a similar manner and used within 30 min after collection.
Prekallikrein-deficient plasma was purchased from Dr. C. Abildgaard (University of California, Davis, Calif.). Factor XI-deficient plasma was purchased from George King Biomedical (Overland Park, Kan.). Factor XII-deficient plasma was obtained from an individual with congenital deficiency having a level of <0.01 U/ml. Plasma from HMW kininogendeficient individuals (<0.02 U/ml) was kindly supplied by Dr. Thomas Waldman (Fitzgerald), Dr IgG were present in the final preparation. The prekallikrein ran as a single band of 88,000 daltons on reduced or nonreduced sodium dodecyl sulfate disc gel electrophoresis (11) .
In some experiments, the prekallikrein used was obtained from the step before the anti-IgG agarose step and had IgG as the sole detectable impurity. No differences were noted between these two fractions regarding functional or immunologic activity. Antiserum to kallikrein completely neutralized the amidolytic activity of the activated enzyme. Kallikrein was prepared by incubating 50 ,il of the prekallikrein described above (1 U/ml) with 10 ,ul XIIf (50 ,ug/ml) at 37°C for 8 min.
HMW kininogen was purified by a modification of the method of Habal and Movat (12) by employing chromatography on QAE-Sephadex, ammonium sulfate precipitation, chromatography on CM-Sephadex and chromatography on SPSephadex. An additional step was added to the published procedure. A 2.5 x 60-cm column containing SP-Sephadex was equilibrated with 0.03 M sodium acetate buffer, pH 6.0, containing 0.05 M NaCl. After application ofthe HMW kininogen from the CM-Sephadex steps and washing with the starting buffer, a linear gradient from 0.2 to 0.4 M NaCl in the same buffer was used to elute the HMW kininogen. The purified HMW kininogen emerged near the end of the gradient and had a specific activity of 15 U/mg coagulant activity. The protein was a single component of 120,000 daltons on sodium dodecyl sulfate-disc gel electrophoresis. No contamination was detected by functional assays for Factor XI, Factor XII, or prekallikrein coagulant activity, or by immunological assays for a2-macroglobulin, Cl-inhibitor, antithrombin III, a,-antitrypsin, or kallikrein.
The Factor XII fragments were prepared as described previously (13) . No contamination with Factor XII or high molecular weight activator (13) was detected in purified XIIf. There was no detectable contamination with Factor XI, plasminogen, plasmin, HMW kininogen, prekallikrein, or kallikrein. For use in functional studies, XIIf was stabilized with bovine serum albumin at a final concentration of 0.5 mg/ml.
Kallikrein was prepared by the method of Bagdasarian et al. (14) . It contained no detectable HMW kininogen, Cl-inhibitor a2-macroglobulin, al-antitrypsin, plasminogen, or plasmin but contained 8% IgG. This kallikrein preparation was used only for the production of antiserum. Antiserum to kallikrein was prepared in rabbits by the method of Bagdasarian et al. (14) . It was adsorbed with prekallikrein-deficient plasma to render it monospecific.
Immunological methods Electroimmunodiffusion EID. This was performed according to the method of Laurell (15) using 1% agarose in B-2, [/2 = 0.0375. Kallikrein antiserum was used at a final concentration of 1.6%. Electrophoresis was performed for 16 h at 14°C at 50 V. The plates were soaked and stained as previously described (16 plasma was added to 50 Al of a mixture containing 0.1% inosithin in 0.15 M NaCl and 10 mg/ml kaolin. 50 ,ul of prekallikrein-deficient plasma was introduced and the mixture wvas then incubated for 1 min at 37°C before recalcification with 50 ,ul of 0.025 M CaC12. Note that in this method the HMW kininogen present in prekallikrein-deficient plasma is not allowed to interact with the prekallikrein in the sample plasma until that plasma is exposed to kaolin. In the reconstitution experiments with HMW kininogen, the samples to be assayed were first diluted with sodium barbital buffer in saline, pH 1.4, and then added to purified HMW kininogen or additional buffer. The samples were incubated for 10 min at 25°C before adding them to the other reagents. They were then assayed similarly to the standard curve and expressed as the percent of normal pooled plasma. In procedure B, where samples containing free prekallikrein were assayed, they were allowed to come into contact with the prekallikrein-deficient plasma before kaolin addition. The results were similar to those obtained when the free prekallikrein sample was preincubated with purified HMW kininogen because prekallikrein-deficient plasma contains normal levels of HMW kininogen. There was no variation in results whether the sample was incubated briefly with the prekallikrein-deficient plasma, (<10 s) or as long as 10 min.
In the esterolytic assay, samples were assayed for their ability to hydrolyze the synthetic substrate TAMle according to the method of Siegelman et al. (18) as modified by Colm-an et al. (19) . Plasma was either incubated vith 0.1 M sodium phosphate, pH 7.6, containing 0.15 M NaCl or with HMW kininogen for 10 min at 25°C before activation of the plasma prekallikrein by kaolin.
Kallikrein inhibitors were depleted by either of two methods, using chloroform or acidification followed by neutralization (20) . Without an activating agent, plasma prepared under these conditions hydrolyzed <3 ,umol TAMe/ml per h.
The amidolytic activity of kallikrein was determined using the chromogenic substrate H-D-Pro-Phe-Arg-p-nitroanilideHCl (21) . The assay was modified by using 0.1 MI sodium phosphate buffer containing 0.15 M NaCl, pH 7.6, and substrate at a final concentration of 0.09 mM.
Immunoassay for other proteins. L-C Partigen IgG plates for RID wvere used for the quantitative measturement of IgG according to the procedture described bv the mnanufacturer. Cl-inhibitor, _2-macroglobulin, antithrombin III, and a,-antitrypsin were quantitated by RID as described bv Mancini et al. (17) . Assay ofFactorXI, FactorXII, and HMWkininogen. These were measutred by a modificatioon of the partial thromboplastin time (22) using specifically deficient plasma as previously described (1). 1 U is defined as that amount wvhich is present in 1 ml of normial pooled plasmla.
RESULTS
Increasing concentrations of purified H.M\V kininogen were incubated with HM1W kininogen-deficient plasima. Prekallikrein antigen was then assayed by both RID and EID (Fig. 1A) . In the absence of HMW\ kininogen, this plasma contained, by these two assays, 35 and 20% prekallikrein antigen, respectively compared to normal pooled plasma used as a reference. The apparent pre- HMW kininogen. To demonstrate the basis of the increase observed, we studied prekallikrein antigen by IEP in plasma deficient in HMW kininogen as well as in normal plasma. A single precipitin arc near the origin was observed in HMW kininogen-deficient plasma ( Fig. 2A) . This arc was identical in position to purified prekallikrein or kallikrein (Fig. 2B) and therefore represented the position offree prekallikrein. In contrast in normal plasma, prekallikrein appeared as an elongated arc extending anodally. The anodal extension gave a reaction of identitv with the free portion, and thus represented another form of this antigen. The anodal extension was reproduced in HMW kininogendeficient plasma by incubating the plasma with purified HMW kininogen ( Fig. 2A) and was also formed by adding HMW kininogen to either purified prekallikrein or kallikrein (Fig. 2B) A dose response of prekallikrein-HMW kininogen formation was demonstrable by crossed IEP using purified components (Fig. 3) . Purified prekallikrein (A) remained close to the origin resulting in a small symmetrical precipitin arc. Addition of 0.2 U/ml HMW kininogen to the same amount of prekallikrein (B) resulted in a decrease of the arc corresponding to free prekallikrein, and the formation of a new precipitin arc migrating more anodally. The height and area of the new arc was further increased upon addition of 0.5 U/ml HMW kininogen (C). This observation was similar to that seen on IEP.
The dependence of prekallikrein activity on HMW kininogen was also studied in HMW kininogen-deficient plasma (Fig. 4) . In the prekallikrein coagulant assay, this plasma showed only 30% of normal activity. A dose-related increase in activity was noted when HMW kininogen was added to the plasma, reaching normal values at HMW kininogen concentrations of -0.2 U/ml. HMW kininogen-deficient plasma showed no esterase activity after activation with kaolin for 1 min, as previously observed (1) . When concentrations of HMW kininogen as high as 0.5 U/ml were added to the plasma before kaolin activation, -45% of the esterase activity as compared to the reference plasma was seen. However, if kallikrein inhibitors were depleted by treating the plasma with CHCI3 before addition of HMW kininogen at a concentration of 0.2 U/ml, normal levels of kallikrein esterase activity were attained.
Because Crossed IEP-dose response of purified HMW kininogen on purified prekallikrein. 6 ,ug of purified prekallikrein in B-2 buffer (r/2 = 0.0375) was incubated alone (A) or with 0.2 U/ml (B) or 0.5 U/ml purified HMW kininogen (C) for 10 min at 37°C. Dimension 1 was run for 3.5 h at 250 V at 14WC on a single glass plate (8.3 x 9.4 cm). After electrophoresis, the samples from dimension 1 (1.5-cm strips) were sliced and transferred to individual 3- individuals with this deficiency (Table I) . Four Insufficient plasma was available for prekallikrein coagulant assays after the antigen assays were completed. U/ml HMW kininogen to native plasma increased the mean arginine esterase activity (kallikrein) from 102 to 132 umol TAMe hydrolyzed/h per ml (P < 0.001 by paired Student's t test). The increase was uniform and the correlation of the activity in the native plasma with the activity in the same plasma supplemented with HMW kininogen was excellent (r = 0.91, P < 0.001). If, however, esterase activity was measured in the plasma after CHC13 treatment, the mean activity rose to 168 ,umol TAMe hydrolyzed/h per ml (P < 0.001). There was a reasonable correlation between the activity in native and CHCl3-treated plasma (r = 0.66, P < 0.01). However, in CHCl3-treated plasma no increase in esterase activity was noted after supplementation with HMW kininogen, suggesting that the naturally occurring kallikrein inhibitors were limiting the activation or activity. In fact, a small but statistically significant decrease to 152 ,umol TAMe hydrolyzed/h per ml (P < 0.001) was observed when additional HMW kininogen was added to the CHCl3-treated normal plasma. The results ofthis experiment are consistent with those of Kluft (21) who observed maximal activation of prekallikrein by kaolin in normal plasma at 20 s at 25°C. A decrease of 30%, observed at 1 min, was attributed to inactivation of the kallikrein activity by plasma inhibitors such as CI-inhibitor.
The effect of inhibitor is even more evident when
XIIf is used to activate purified prekallikrein (Fig. 5) previously (9) , the rate of prekallikrein activation by XIIf is enhanced by purified HMW kininogen. However, when native prekallikrein-deficient plasma (a source of HMW kininogen and inhibitor blut not prekallikrein) was added to purified prekallikrein and then activated by XIIf, a maximiium of only 30% of its potential activity was reached as compared to the same amount of purified prekallikrein activated by Xllf in the presence of buffer. A decrease in activity oceurred after 1 min which was apparently a result of the inhibition of kallikrein activity by naturally occurring kallikrein inhibitors in the prekallikrein-deficient plasma. This hypothesis is confirmed by the finding that inactivation of inhibitors (by acid treatment) in the prekallikrein-deficient plasma before the addition of the purified prekallikrein and its subsequent activation by XIIf, resulted in rapid and complete activation of the prekallikrein. The level of activity in the prekallikrein-buffer mixture and the prekallikreinprekallikrein-deficient plasma (acid-treated) mixture was identical except that the latter attained the fully activated level at 3 min whereas even after 9 min, the prekallikrein-buffer mixture had not reached full activati()n. The acceleration of the prekallikrein activation was a result of the presence of HMW kininogen and possibly other potentiators (23) derived from the prekallikrein-deficient plasma which were now free to operate without interference by plasma inhibitors. A mixture of purified prekallikrein and purified HMW kininogen (0.2 U/ml), after activation by XIIf, behaved similarly to the prekallikrein-prekallikrein-deficient plasma (acid-treated) mixture, in that, the rate of activation of the purified prekallikrein was accelerated by the presence of the HMW kininogen. This observation further supports the hypothesis that a deficiency of HMW kininogen in plasma can retard the rate ofprekallikrein activation long enough to be significantly affected by plasma kallikrein inhibitors.
Because we observed free prekallikrein existing in normal plasmla, in addition to complexed prekallikrein (Fig. 2) , we sought to demonstrate whether it could form additional complex if combined with purified HMW kininogen and give rise to increased apparent prekallikrein antigen. Upon addition of purified HMW kininogen to normal pooled plasma, an increase in apparent prekallikrein concentration was observed both in RID (35%) and EID (50%) (Fig. 6 ). Further evidence was seen when normal plasma from a single donor was gel filtered (Fig. 7) . Two peaks of prekallikrein coagulant activity were found. One peak, in the area of the previously described complex (24) having an Mr of -280,000 daltons, represented -89% of the total prekallikrein coagulant activity, whereas the other activity peak was observed in the area of free prekallikrein (Mr 120,000). Addition of the column fraction to the prekallikrein-deficient plasma before kaolin addition in the prekallikrein coagulant assay, resulted in a twofold increase of activity in the 120,000 Mr peak. Because the prekallikrein-deficient plasma contains HMW kininogen, it allowed the formation of the prekallikrein-HMW kininogen complex with the free prekallikrein in the column fractions. The 
DISCUSSION
The occurrence of multiple apparent defects in the hemostatic system is not unique to the contact phase.
Combined Factor V and Factor VIII deficiencies are documented (25) and the complexities of the overlapping defects in hemophilia A and von Willebrand's disease are well known (26) . Several explanations have been offered to account for the combined deficiency of HMW kininogen and prekallikrein including genetic linkage (27) . Nevertheless, the possibility must be considered that functional or structural relationships between these two proteins might directly influence assay methods. Although the major defect in the HMW kininogen-deficient individuals (1) (2) (3) (4) (5) 28) (27) confirmed the existence of the complex by adsorbing both prekallikrein and HMW kininogen from plasma with either monospecific antiserum against kallikrein or HMW kininogen. Furthermore, both proteins are important for optimal activation (7, 8) and activity (9) ofthe various forms of Factor XII.
Our experiments demonstrate both qualitative and quantitative modification of prekallikrein antigen migration and reactivity both in purified preparations as well as in normal and HMW kininogen-deficient plasma by the addition of purified HMW kininogen. Observations ofthe immunoelectrophoretic pattern of purified prekallikrein or plasma deficient in HMW kininogen revealed a single, discrete precipitin arc, which is in agreement with the observations of Donaldson et al. (27) . We were able to demonstrate, however, that the addition of purified HMW kininogen extended the precipitin arc anodally while retaining antigenic identity to the more cathodal arc, similar to the pattern observed in normal plasma. Moreover we assured that the size ofthe complex was not limiting. The cause of the larger ring diameter of the complex is unknown but may be the result of an alteration in the number of exposed antigenic sites in the complex (for example, prekallikrein enclosing a HMW kininogen core) or to conformational changes in the complexed molecule resulting in changes in its molecular dimensions. To detect neoantigenic sites, the prekallikrein antibody was adsorbed with HMW kininogendeficient plasma. However, the adsorbed antiserum still recognized both free prekallikrein and prekallikrein-HMW kininogen complex although the titer appeared diminished. Crossed IEP, however, suggested that the antigenic reactivity of the complex is different from free prekallikrein because the height and integrated area of the complex was increased with increasing amounts of HMW kininogen. Thus, it appears that the apparent deficiency of prekallikrein antigen in HMW kininogen-deficient plasma was a result of the absence of HMW kininogen and not prekallikrein.
Although decreased functional prekallikrein activity has previously been reported in three individuals (1, 2, and 4), we found normal prekallikrein levels to be present in the plasma of these individuals if we performed the assays after inactivating plasma inhibitors and then supplementing it with HMW kininogen. The presence of inhibitors was also a determinant of the extent of prekallikrein activation and kallikrein activity in normal plasma. Kallikrein esterase activity was higher in plasma depleted of kallikrein inhibitors than in native plasma, although the two measurements remained closely correlated. Thus, activation of native plasma prekallikrein by kaolin for 1 min at 25°C gave an estimate of total prekallikrein but actually underestimated the absolute concentration. The addition of HMW kininogen to normal native plasma may augment kallikrein esterase levels by increasing the rate of activation, in part, by forming additional complex with the free prekallikrein. However, the failure of HMW kininogen to augment prekallikrein activation in CHC13-treated plasma suggests another role for the cofactor. It is possible that when HMW kininogen binds to kallikrein, it retards the destruction of the kallikrein activity by competing for binding sites that would otherwise be available to Cl-inhibitor. The importance of plasma inhibitors is underscored when activation proceeds more slowly exemplified by the experiments using XIIf and purified prekallikrein.
The concept of free prekallikrein existing in equilibrium with the prekallikrein-HMW kininogen complex was supported by the observation of a 120,000-Mr peak on gel filtration of normal plasma in addition to the predominant 280,000-Mr peak previously reported by Mandle et al. (24) . Differences in methodology of the prekallikrein coagulant assay may explain the failure of Mandle et al. (24) to note the uncomplexed prekallikrein, although a peak representing 11% of the activity could easily have been missed. Further evidence of free as well as complexed prekallikrein in normal plasma was observed on IEP in both fresh and frozen plasma.
The data suggest that assays of plasma prekallikrein alone do not assure accurate quantitation unless a concentration of at least 0.2 U/ml HNIW kininogen is intrinsically present in the sample or is added to the assay system. The absence of HMW kininogen resuilts in apparently low prekallikrein levels because of (a) incomplete surface activation in the coagulant assay; (b) incomplete activation coupled with greater inhibition in the esterolytic and amidolytic assays; and (c) decreased antigenic reactivity.
